A Phase III trial is assessing cretostimogene grenadenorepvec for BCG-unresponsive non-muscle invasive bladder cancer. Credit: SciePro / Shutterstock.com.

Oncolytic immunotherapy company CG Oncology has secured $105m in a crossover funding round to advance its clinical-stage bladder cancer programmes.

The financing round was led jointly by new investors Foresite Capital and TCGX. BVF Partners, Avidity Partners and Janus Henderson Investors joined them.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Current investors Acorn Bioventures, Decheng Capital, Ally Bridge Group, Malin Corporation, RA Capital Management and Longitude Capital also took part in the round.

CG Oncology plans to use the oversubscribed financing to progress clinical programmes in bladder cancer and obtain approval from the US Food and Drug Administration (FDA).

The programmes include the single-arm, Phase III BOND-003 monotherapy clinical trial of cretostimogene grenadenorepvec. This could potentially treat patients with high-risk non-muscle invasive bladder cancer (NMIBC) not responsive to bacillus Calmette-Guerin (BCG).

See Also:

Cretostimogene grenadenorepvec is an oncolytic immunotherapy agent administered intravesically. It is being evaluated in a Phase II trial along with Keytruda (pembrolizumab) for the same indication.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The agent is also being analysed along with Opdivo (nivolumab) for the treatment of other bladder cancer types.

CG Oncology CEO Arthur Kuan stated: “We are excited to welcome leading life science investors who share our vision of developing cutting-edge therapeutics addressing unmet medical needs in bladder cancer. 

“Our lead asset, cretostimogene grenadenorepvec, continues to make significant clinical progress in bladder cancer in both monotherapy and combination studies. We are encouraged to see our treatments get closer to being available to bladder cancer patients worldwide.”